06:41 AM EST, 01/28/2025 (MT Newswires) -- BriaCell Therapeutics Corp. ( BCTX ) , a clinical-stage biotechnology company, overnight Monday said it had completed a share consolidation of the company's issued and outstanding common shares on the basis of one post-consolidation common share for every fifteen pre-consolidation common shares. It said the consolidation is being implemented to ensure that the company continues to comply with the listing requirements of The Nasdaq Capital Market.

A statement noted the post-consolidation common shares are expected to commence trading on the Toronto Stock Exchange and the Nasdaq at market open on January 29, 2025.

BCT was down $0.03 or 5.2% on the TSX yesterday, and is trading near 52 week low levels in both Canada and the United States.